How much does platinib cost after entering the medical insurance?

Pralsetinib is an oral anti-cancer drug. It is an inhibitor of the receptor tyrosine kinase RET. It is mainly used to treat a variety of cancers caused by RET gene mutations. Platinib can accurately inhibit the phosphorylation of RET and its downstream molecules, effectively curb the proliferation of cells expressing RET gene mutations, and provide a new treatment strategy for cancer patients.

Specifically, platinib has shown excellent results in the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), especially in patients with RET fusion gene-positive patients. Clinical data shows that Platinib can effectively reduce tumor size, relieve symptoms such as cough and chest tightness, and prolong the survival time of patients. In addition, Platinib is also indicated for the treatment of advanced or metastatic RET-mutated medullary thyroid cancer (MTC), as well as radioactive iodine-refractory advanced or metastatic RET fusion-positive thyroid cancer. In the treatment of these conditions, platinib also shows significant therapeutic effects.

It is worth mentioning that as the first selective RET inhibitor approved for marketing in China, platinib's efficacy and safety have been widely verified. However, patients should also pay attention to possible side effects when using it, such as high blood pressure, constipation, etc., and strictly follow the doctor's instructions when taking medication.

Platinib is now available in the domestic market. Patients do not need to purchase it overseas and can purchase it directly in China. This drug, produced by Catalent CTS in the United States, contains 120 capsules of 100 mg per box and is priced at about 20,000 yuan. However, it should be noted that Platinib has not yet been included in my country’s medical insurance system. At the same time, the overseas version of Platinib, with a specification of 100 mg and 60 tablets, has a price of up to 159,000 yuan per box in the United States, while in Europe it is about 45,000 yuan. It is worth mentioning that Lucius, Laos has launched a generic version of platinib, and the price of the drug with the same specifications is only about 4,600 yuan.

In general, platinib is a powerful anti-cancer drug targeting RET gene mutations, bringing new treatment hope to patients with many types of cancer. Its unique mechanism of action and significant therapeutic effect make it important in the field of anti-cancer.